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Abstract 21 
 22 
We are living in a era of alarming increases in microbial resistance to currently available antibiotics, 23 
and there is a growing need for new pharmaceutical products to treat infectious diseases. The 24 
pomegranate is an edible fruit that has virucidal and antimicrobial activities which is primarily 25 
attributable to the high concentration of hydrolysable tannins. Punicalagin, a high molecular weight 26 
tannin (1084.7), accounts for approximately 70% of the total and is concentrated in the fruit exocarp 27 
(rind). It is the focus of much research, although it is prohibitively expensive to purchase which 28 
presents an obstacle to further exploitation and development. Here we describe a method for the 29 
isolation of punicalagin from pomegranate rind extract and total pomegranate tannins using an 30 
Agilent preparative mass-directed LC-MS single quadrupole ESI-API system, where the ionization 31 
was set as negative and the mass signal acquired in Single Ion Monitoring. Thanks to the automatic 32 
fraction collector, the method can be used in automatic mode and is capable of producing 33 
punicalagin with >95% purity. 34 
 35 
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1. Introduction 44 
 45 
We are currently living in an era of alarming and unprecedented increases in microbial resistance to 46 
our current arsenal of antibiotic drugs, and no new drugs have come onto the market in 30 years or so. New 47 
products are thus urgently needed [1, 2]. In addition, there is a clear predilection by patients for medicines that 48 
are of natural origin compared to synthetic drugs [3, 4].  49 
The fruit of Punica granatum L. (pomegranate) has been used as a healthy and healing fruit for many 50 
years. It has long been used in Middle Eastern and Chinese medicine for its antioxidant, anti-inflammatory [5] 51 
bactericidal [6] and virucidal [7] properties. The phytochemicals constituents of pomegranates include many 52 
chemical species including sugars, flavonoids, anthocyanin, tannins, [8] and can be obtained from  most  parts  53 
of  the  fruit  but  the  exocarp, or rind, has been shown  to  contain  the  highest  concentration  of  polyphenols. 54 
A major class of compounds is the hydrolysable ellagitannins of which punicalagin (2,3-(S)-55 
hexahydroxydiphenoyl-4,6-(S,S)-gallagyl-D-glucose) constitutes up to 70% [Figure 1]. It is a large molecule 56 
(MW 1084.71) and is comprised of 3 moieties: gallagic acid and ellagic acid linked via a glucose unit. The 57 
molecule naturally adopts one of two anomeric forms, ?and ?, depending on whether the glucose is in the 58 
boat or chair conformation, and the two exist in a 1:2 ratio under standard conditions. 59 
Ongoing research shows that punicalagin is primarily responsible for antimicrobial, anti-inflammatory 60 
and virucidal properties of PRE. The microbicidal activities of PRE and punicalagin have been shown to 61 
undergo significant potentiation when co-administered with metal ions, eg Zn (II) [9, 10]. Punicalagin therefore 62 
has potential as a therapeutic agent as outlined; however, it is very expensive to purchase (eg £217 for 10 63 
milligrams from one major supplier) which presents a barrier to further development, as substantial quantities 64 
are required to carry out the necessary pre-clinical drug development work.  65 
PRE is typically prepared from pomegranate rinds by extraction into boiling water [9] followed by 66 
centrifugation and filtration. The non-tannin components of PRE can be removed by column chromatography 67 
to yield concentrated total pomegranate tannins (TPT), for example using Amberlite XAD-16 resin. 68 
Punicalagin may then be isolated by column chromatography using a Sephadex LH-20 column which entails 69 
a complex gradient elution [11] or by countercurrent chromatography [12]. The methods typically used to 70 
isolate punicalagin thus require numerous time-consuming laboratory steps and lengthy sample preparation.  71 
Given the need for new antimicrobial molecules has arisen over recent years, fast and reproducible 72 
methods to isolate significant amounts of antimicrobial molecules has the potential to expedite the 73 
development of new therapeutic products. Mass-directed purification is a type of preparative LCMS in which 74 
the instrument may be set to collect column eluate upon detecting a pre-selected mass or mass range, once the 75 
chromatographic conditions have been established. These sophisticated instruments are available from a 76 
number of manufacturers including Waters and Shimadzu, although we have in our laboratory an Agilent 1260 77 
Infinity Automated LC/MS Purification System [13]. In the current work we describe a method for the isolation 78 
of high-purity punicalagin using this system. 79 
 80 
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2. Materials and methods 81 
 82 
2. 1 Materials 83 
 84 
Amberlite XAD-16 (Alfa Aesar), LCMS-grade water and methanol were purchased from Fisher Scientific, 85 
Loughborough, UK. Pomegranates, of Spanish origin, were purchased from a local store.  86 
 87 
 88 
 89 
2.2 Preparation of Pomegranate Rind Extract (PRE) 90 
 91 
The rinds from five pomegranates were cut in small pieces of approx. 2cm and blended in deionized water, 92 
25% w/v, before being boiled for 10 min and transferred to 50mL tubes and centrifuged 7 times at 5840rpm 93 
for 30 min on each occasion. The supernatant was then vacuum filtered through 0.45µm nylon membranes 94 
(Whatman, UK) to yield a clear dark yellow-orange solution which was then freeze-dried and stored  at  -20°C  95 
until required [14]. 96 
 97 
 98 
2.3 Preparation of Total Pomegranate Tannins (TPT) from PRE  99 
 100 
Based on a previously reported method [11] a glass column was  slurry-packed  with  50g  of  Amberlite  XAD-101 
16  resin  in  degassed  and  deionized  water.  This was then washed with methanol, followed by deionized 102 
water, and then was left overnight to equilibrate. A 2cm layer of sand was added to the top and the bottom.  103 
Freeze-dried PRE was reconstituted in deionized water at a concentration of 200 mg/mL and loaded onto the 104 
column.  Firstly, the water-soluble components were washed out using a copious amount of water, then the 105 
TPT fraction was eluted after washing with 70mL of methanol and collected.  This solution was then rotary 106 
evaporated using a Buchi instrument with the temperature set at 40°C and the vacuum at 50mbar. The TPT 107 
product was stored at 2-4 °C until further use. Analysis of the tannin-free fraction (section 2.4) confirmed that 108 
no tannins were present (data not shown). 109 
 110 
2.4 Analytical HPLC analysis of TPT 111 
 112 
The TPT was analysed using an Agilent 1100 system fitted with a Kinetex C18 150 x 4.6mm 5µm 100Å RP 113 
column (Phenomenex, Macclesfield, UK).  Based on a previous method [9] a gradient mobile phase was used 114 
composed  of:  solvent  A  H2O  +  0.1%TFA and  solvent  B: MeOH + 0.1%TFA. The gradient timetable 115 
started with 5%B, 0-3 min 10%B, 3-15 min 20%B, 15-20 min 40%B, 20-25 min 60%B, 25-27 min 5%B, 27-116 
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35 min 5%B. A 1 mg/mL sample in deionized H2O was prepared, the injection volume was 20 µL and the 117 
detection was performed at a wavelength of 258 nm with a UV detector.   118 
 119 
 120 
2.5.  Semi-preparative Isolation of Punicalagin using an LC-MS system 121 
 122 
The isolation was performed using a modular semi-preparative LC-MS ESI-AP single quadrupole system with 123 
automatic fraction collector (Agilent Technologies, Stockport, UK).  Waters X-Select CSH C18 OBD 5µm 124 
130Å columns were used:  firstly a 50 x 10mm scout column which was used to set up a reliable extraction 125 
method, then a 250 x 19mm semi-preparative column.  The solvents used were H2O (channel A) and MeOH 126 
(channel B); no mobile phase acidification was used. The separation was performed in Single  Ion  Monitoring  127 
(SIM)  negative  ionization mode,  with  a  capillary  voltage  of  4000V,  drying  gas  temperature  of 350°C 128 
and  gas  nebulizer  pressure of  32  psi [15]. The threshold of the automatic fraction collector was set at 2000. 129 
 130 
The gradient was scaled from the analytical method to be reproducible with these columns.  Firstly, the scout 131 
column method was converted from the analytical one, and a run was performed to check the reliability of the 132 
separation.  The sample was 100mg/mL in H2O and 300µL were injected.  Further runs were carried out to 133 
control the consistency of the separations.  The gradient used with this column started at t0 with 5%B, 0-0.38 134 
min 10%B, 0.38-1.80 min 20%B, 1.80-2-39 min 40%B, 2.39-2.98 min 60%B, 2.98-3.22 min 5%B, 3.22-4.16 135 
min 5%B.  Although even with this column was possible to isolate punicalagin, only low amounts were 136 
collected, so the method evolved to the big semi-preparative column.  The gradient for this column started 137 
with 5%B, 0-7.77 min 10%B, 7.77-33-36 min 20%B, 33.36-44.02 min 40%B, 44.02-54.69 min 60%B, 54.69-138 
58.95 min 5%B, 58.95-76.01 min 5%B. This sample load was 225mg in 1.5mL H2O. The flow rate for both 139 
the columns was 20mL/min.  Both manual and automatic collection were performed.  As already stated above, 140 
the threshold for the automatic collection was set above 2000. The samples obtained were then dried to yield 141 
the purified punicalagin; firstly, the methanolic fraction was evaporated using a Buchi rotary evaporator (50 142 
mbar, 50 °C), then the remaining solvent (aqueous) was removed by freeze-drying.     143 
 144 
 145 
3. Results and discussions 146 
 147 
As can be seen in the analytical HPLC chromatogram [Figure 2], the two anomers of punicalagin were well 148 
separated in the preparative LCMS method described.  The two main peaks α and β punicalagin eluted with a 149 
different concentration of solvent B and always tend to an approximate ratio of 1:2 ratio.  The peak at the end 150 
can be identified as ellagic acid, one of the   major  building  blocks  of  punicalagin. The analysis of the TPT 151 
was performed to prove the presence of punicalagin, so it was possible to proceed with the purification.  152 
Because of the differences in the stationary phase between the preparative and the analytical columns, the 153 
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chromatogram of the preparative HPLC doesn’t appear well separated, but thanks to the mass spectrometric 154 
collection triggering, it was still possible to isolate highly pure punicalagin. Figure 2 shows the plot of the run 155 
with the small scout column.  The vertical lines show the windows in which the punicalagin (alpha the first 156 
and beta the second) was collected; the ratio of the two isomers was found also in the mass chromatogram.  157 
 The analytical resolution of punicalagin utilises acidification, typically by trifluoroacetic acid (TFA) 158 
[9]. In LCMS the preferred acidifying reagent is formic acid as, compared to TFA, it tends not to leave behind 159 
residual molecules. However, we found that when the punicalagin fractions were evaporated to dryness, it was 160 
discovered that nearly all the punicalagin had degraded. This was attributed to the increasing acidity that 161 
accompanied drying as the acid was also increasing in concentration. Consequently, it was decided to omit 162 
altogether the formic acid to ensure greater stability of the punicalain, albeit at the expense of superior 163 
chromatographic resolution. 164 
The semi-preparative column report [Figure 3] shows a different HPLC chromatogram and a similar 165 
SIM chromatogram, probably due to the different sample loading in the two columns: in the small scout column 166 
it was closer to the optimal loading. In this case, even though both the little signals in the mass spectrum were 167 
slightly above 2000, the only fraction collected was the high peak at 22 min. For completeness, each fraction 168 
collected was re-run through the preparative LC-MS [Figure 4] to check the purity of the punicalagin, and all 169 
the signals detected were approximately the same: the differences represented the different grade of purity 170 
(average of >95% pure).  These tests were performed after 1 hour.  171 
The purity of the collected punicalagin product was determined by analytical HPLC [9]. Figure 5 172 
shows that 95% of the integrated areas (compared to the total areas) was accounted for by the punicalagin 173 
anomer peaks.  Interestingly, we attempted to collect individual anomers separately, by programming the 174 
instrument to collect at times corresponding to ?and ?punicalagin accordingly - it would be of interest to 175 
determine if the anomers give rise to differing biological (eg anti-microbial, anti-inflammatory) activities. 176 
However, even though collections were seemingly successful using the acid-free elution, it was noted that 177 
each ‘purified’ anomer reverted to the 1:2 ratio after drying, with β-punicalagin is the more abundant anomer 178 
at neutral pH [16]. 179 
 180 
4. Conclusions 181 
 182 
A rapid, reliable and automatable method to isolate punicalagin from TPT was developed using the 1260 183 
Infinity Automated LC/MS purification system. This facilitating the development work in order to bring to 184 
market new punicalagin-based antimicrobial products at a time of great need whilst avoiding large expenses 185 
to purchase it from suppliers. Work is ongoing to purify punicalagin directly from PRE, thus avoiding the prior 186 
concentration of TPT through Amberlite.  However, the TPT separation step is not onerous, and does provide 187 
a material that is freely soluble in methanol, useful for easy injection into the LCMS. 188 
 189 
 190 
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